You are encouraged to report any side effects that might be related to a Fresenius Kabi product. Talk to your doctor, consultant, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information leaflet. You can report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ (for UK residents) or http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects (for residents of the Republic of Ireland).
Side effects can also be reported directly by email to Fresenius Kabi via pharmacovigilance.gb@fresenius-kabi.com. By reporting side effects you can help to provide more information on the safety of this medicine.
If you interact with us, e.g. as a customer, supplier, patient, healthcare professional or website user, we collect and use your personal data while adhering to the data protection principles. This means that we collect and use your personal data only lawfully, fairly, in a transparent manner and only for the purposes they were collected.
For further information on how Fresenius Kabi processes your personal data related to adverse events, please refer to our Privacy Policy.
If you have a product complaint, please contact Fresenius Kabi: Phone: +44 (0)1928 533758
E-mail: FK.Complaints-UK@fresenius-kabi.com
For Fresenius Kabi Medical Information please contact: Tel +44 (0)1928 533 533
Fresenius Kabi are unable to provide advice on personal medical matters. For advice of this nature please contact your doctor or healthcare professional.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard (for UK residents) or see http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects (for residents of the Republic of Ireland). By reporting side effects, you can help provide more information on the safety of this medicine.
We use cookies to ensure the correct functioning of this website, provide the best possible service to you, enhance your user experience, and optimise our website. Find out more about how we collect and use your data and how you can change your settings.
You are leaving the KabiCare website now. Please note that Fresenius Kabi have no affiliation or control over the content available on external third-party websites.
ContinueYou are now leaving the KabiCare website and will be re-directed to your local Fresenius Kabi corporate website.
For general product information about IDACIO (adalimumab) for members of the public, please refer to the Patient Information Leaflet and the Summary of Product Characteristics(SmPC).
If you have any questions, please consult your healthcare professional team.
Continue